VIPR1
(Preusmjereno sa stranice RDC1)
| edit |
| Receptor vazoaktivnog intestinalnog peptida 1 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 Prikaz baziran na PDB 1OF2 | |||||||||||
| Dostupne strukture | |||||||||||
| 1OF2, 1OGT, 3B3I | |||||||||||
| Identifikatori | |||||||||||
| Simboli | VIPR1; HVR1; II; PACAP-R-2; PACAP-R2; RDC1; V1RG; VAPC1; VIP-R-1; VIPR; VIRG; VPAC1; VPAC1R; VPCAP1R | ||||||||||
| Vanjski ID | OMIM: 192321 MGI: 109272 HomoloGene: 3399 IUPHAR: VPAC1 GeneCards: VIPR1 Gene | ||||||||||
| |||||||||||
| Pregled RNK izražavanja | |||||||||||
 | |||||||||||
| podaci | |||||||||||
| Ortolozi | |||||||||||
| Vrsta | Čovek | Miš | |||||||||
| Entrez | 7433 | 22354 | |||||||||
| Ensembl | ENSG00000114812 | ENSMUSG00000032528 | |||||||||
| UniProt | P32241 | P97751 | |||||||||
| RefSeq (mRNA) | NM_001251882.1 | NM_011703.4 | |||||||||
| RefSeq (protein) | NP_001238811.1 | NP_035833.2 | |||||||||
| Lokacija (UCSC) | Chr 3: 42.53 - 42.58 Mb | Chr 9: 121.55 - 121.58 Mb | |||||||||
| PubMed pretraga | [1] | [2] | |||||||||
Receptor vazoaktivnog intestinalnog peptida 1 (VPAC1) je protein koji je kod ljudi kodiran VIPR1 genom.[1] VPAC1 je izražen u mozgu (cerebralni korteks, hiokampus, amigdala), plućima, prostati, perifernim krvnim leukocitima, jetri, tankim crevima, srcu, slezini, posteljici, bubrezima, grudnoj žlezdi i testisima.[2][3][4]
VPAC1 je receptor za neuropeptid vazoaktivni intestinalni peptid (VIP). Taj peptid učestvuje u relaksaciji glatkih mišića, egzokrinoj i endokrinoj sekreciji, i protoku vode i jona u plućima i intestinalnom epitelnom tkivu. Njegovo dejstvo se ispoljava putem integralnih membranskih receptora asociranih sa G proteinima koji aktiviraju adenilat ciklazu.[1]
VIP deluje na autokrini način putem VPAC11 da inhibira proliferaciju megakariocita i indukuje formiranje protrombocita.[5][6]
- ↑ 1,0 1,1 „Entrez Gene: VIPR1 vasoactive intestinal peptide receptor 1”.
- ↑ Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. (1992). „Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.”. Neuron 8 (4): 811–819. DOI:10.1016/0896-6273(92)90101-I. PMID 1314625.
- ↑ Usdin TB, Bonner TI, Mezey E. (1994). „Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.”. Endocrinology 135 (6): 2662–2680. DOI:10.1210/en.135.6.2662. PMID 7988457.
- ↑ Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ. (1995). „Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene”. Proc Natl Acad Sci USA 92 (7): 2939–2943. DOI:10.1073/pnas.92.7.2939. PMC 42334. PMID 7708752.
- ↑ Nam, C.; Case, A. J.; Hostager, B. S.; O’Dorisio, M. S. (2008). „The Role of Vasoactive Intestinal Peptide (VIP) in Megakaryocyte Proliferation”. Journal of Molecular Neuroscience 37 (2): 160–167. DOI:10.1007/s12031-008-9119-x. PMID 18663606.
- ↑ Freson, K.; Peeters, K.; De Vos, R.; Wittevrongel, C.; Thys, C.; Hoylaerts, M. F.; Vermylen, J.; Van Geet, C. (2007). „PACAP and its receptor VPAC1 regulate megakaryocyte maturation: Therapeutic implications”. Blood 111 (4): 1885–1893. DOI:10.1182/blood-2007-06-098558. PMID 18000164.
- „Quaternary structure of rabbit skeletal muscle glycogen synthetase” [Quaternary structure of rabbit skeletal muscle glycogen synthetase]. Doklady Akademii Nauk SSSR 222 (4): 997–1000. 1975. PMID 807467.
- Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ (1995). „Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene”. Proc. Natl. Acad. Sci. U.S.A. 92 (7): 2939–43. DOI:10.1073/pnas.92.7.2939. PMC 42334. PMID 7708752.
- Couvineau A, Gaudin P, Maoret JJ, et al. (1995). „Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP”. Biochem. Biophys. Res. Commun. 206 (1): 246–52. DOI:10.1006/bbrc.1995.1034. PMID 7818527.
- Gagnon AW, Aiyar N, Elshourbagy NA (1994). „Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor”. Cell. Signal. 6 (3): 321–33. DOI:10.1016/0898-6568(94)90037-X. PMID 7917790.
- Sreedharan SP, Patel DR, Xia M, et al. (1994). „Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways”. Biochem. Biophys. Res. Commun. 203 (1): 141–8. DOI:10.1006/bbrc.1994.2160. PMID 8074647.
- Couvineau A, Rouyer-Fessard C, Darmoul D, et al. (1994). „Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains”. Biochem. Biophys. Res. Commun. 200 (2): 769–76. DOI:10.1006/bbrc.1994.1517. PMID 8179610.
- Moody TW, Zia F, Draoui M, et al. (1993). „A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth”. Proc. Natl. Acad. Sci. U.S.A. 90 (10): 4345–9. DOI:10.1073/pnas.90.10.4345. PMC 46507. PMID 8389448.
- Sreedharan SP, Patel DR, Huang JX, Goetzl EJ (1993). „Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor”. Biochem. Biophys. Res. Commun. 193 (2): 546–53. DOI:10.1006/bbrc.1993.1658. PMID 8390245.
- Couvineau A, Fabre C, Gaudin P, et al. (1996). „Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane”. Biochemistry 35 (6): 1745–52. DOI:10.1021/bi952022h. PMID 8639654.
- Pozo D, Guerrero JM, Segura JJ, Calvo JR (1997). „Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells”. Immunopharmacology 34 (2–3): 113–23. DOI:10.1016/0162-3109(96)00131-2. PMID 8886855.
- Couvineau A, Maoret JJ, Rouyer-Fessard C, et al. (1999). „Cloning and functional characterization of the human VIP1/PACAP receptor promoter”. Ann. N. Y. Acad. Sci. 865: 59–63. DOI:10.1111/j.1749-6632.1998.tb11163.x. PMID 9927997.
- Knudsen SM, Tams JW, Wulff BS, Fahrenkrug J (1999). „Importance of conserved cysteines in the extracellular loops of human PACAP/VIP1 receptor for ligand binding and stimulation of cAMP production”. Ann. N. Y. Acad. Sci. 865: 259–65. DOI:10.1111/j.1749-6632.1998.tb11186.x. PMID 9928020.
- Marie J, Wakkach A, Coudray A, et al. (1999). „Functional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymomas from myasthenia gravis patients”. J. Immunol. 162 (4): 2103–12. PMID 9973484.
- Mimuro H, Suzuki T, Suetsugu S, et al. (2000). „Profilin is required for sustaining efficient intra- and intercellular spreading of Shigella flexneri”. J. Biol. Chem. 275 (37): 28893–901. DOI:10.1074/jbc.M003882200. PMID 10867004.
- Nicole P, Maoret JJ, Couvineau A, et al. (2000). „Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding”. Biochem. Biophys. Res. Commun. 276 (2): 654–9. DOI:10.1006/bbrc.2000.3375. PMID 11027527.
- Bajo AM, Juarranz MG, Valenzuela P, et al. (2001). „Expression of vasoactive intestinal peptide (VIP) receptors in human uterus”. Peptides 21 (9): 1383–8. DOI:10.1016/S0196-9781(00)00282-5. PMID 11072126.
- Lara-Marquez M, O'Dorisio M, O'Dorisio T, et al. (2001). „Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells”. J. Immunol. 166 (4): 2522–30. PMID 11160313.
- Martin Shreeve S (2002). „Identification of G-proteins coupling to the vasoactive intestinal peptide receptor VPAC(1) using immunoaffinity chromatography: evidence for precoupling”. Biochem. Biophys. Res. Commun. 290 (4): 1300–7. DOI:10.1006/bbrc.2002.6342. PMID 11812005.
- Dorsam G, Goetzl EJ (2002). „Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor Ikaros”. J. Biol. Chem. 277 (16): 13488–93. DOI:10.1074/jbc.M107922200. PMID 11812772.
- Branch DR, Valenta LJ, Yousefi S, et al. (2002). „VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection”. AIDS 16 (3): 309–19. DOI:10.1097/00002030-200202150-00001. PMID 11834941.